Gujarat Inject Kerala Ltd Stock Price Today (NSE: GUJINJEC)
Fundamental Score
Gujarat Inject Kerala Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gujarat Inject Kerala Ltd share price today is ₹9.79, down 4.21% on NSE/BSE as of 16 September 2026. Gujarat Inject Kerala Ltd (GUJINJEC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹143.41 (Cr). The 52-week high for GUJINJEC share price is ₹136.40 and the 52-week low is ₹8.85. At a P/E ratio of 48.02x, GUJINJEC is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 16.57% and a debt-to-equity ratio of 0.00.
Gujarat Inject Kerala Ltd Share Price Chart — NSE/BSE Historical Performance
Gujarat Inject Kerala Ltd share price chart: -6.04% return over the past month. 52-week high ₹136.40, 52-week low ₹8.85.
Gujarat Inject Kerala Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹10.42 | ₹10.59 | ₹9.76 | ₹9.79 | 3.13L (Cr) | |
| ₹10.28 | ₹10.56 | ₹9.95 | ₹10.22 | 1.47L (Cr) | |
| ₹10.31 | ₹10.50 | ₹10.01 | ₹10.08 | 2.75L (Cr) | |
| ₹10.26 | ₹10.77 | ₹10.06 | ₹10.25 | 4.13L (Cr) | |
| ₹10.80 | ₹10.89 | ₹10.23 | ₹10.26 | 2.66L (Cr) | |
| ₹11.00 | ₹11.40 | ₹10.52 | ₹10.62 | 7.16L (Cr) | |
| ₹11.10 | ₹11.65 | ₹10.61 | ₹11.00 | 2.13L (Cr) | |
| ₹10.85 | ₹11.10 | ₹10.33 | ₹11.10 | 6.52L (Cr) | |
| ₹10.30 | ₹10.84 | ₹9.92 | ₹10.58 | 14.22L (Cr) | |
| ₹10.90 | ₹10.90 | ₹10.40 | ₹10.40 | 6.83L (Cr) |
Gujarat Inject Kerala Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹10.51 | ₹11.65 | ₹9.76 | ₹9.79 | -6.85% | |
| ₹9.76 | ₹13.95 | ₹8.85 | ₹12.17 | +24.69% | |
| ₹129.60 | ₹136.40 | ₹9.70 | ₹10.05 | -92.25% | |
| ₹110.00 | ₹128.00 | ₹108.00 | ₹126.50 | +15.00% | |
| ₹105.25 | ₹116.25 | ₹101.05 | ₹112.25 | +6.65% | |
| ₹82.12 | ₹103.20 | ₹78.00 | ₹103.20 | +25.67% | |
| ₹64.20 | ₹78.22 | ₹63.40 | ₹78.21 | +21.82% | |
| ₹49.98 | ₹64.70 | ₹49.98 | ₹64.20 | +28.45% | |
| ₹35.75 | ₹49.28 | ₹35.75 | ₹48.69 | +36.20% | |
| ₹28.40 | ₹36.40 | ₹27.98 | ₹35.75 | +25.88% | |
| ₹23.99 | ₹29.30 | ₹23.23 | ₹28.28 | +17.88% | |
| ₹20.01 | ₹24.00 | ₹19.51 | ₹23.47 | +17.29% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Gujarat Inject Kerala Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gujarat Inject Kerala Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GUJINJEC across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (16.57%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.93%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Robust Profit Growth (1600.68%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (414.62%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (415.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (49.64% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (79.15% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12521.50x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 4.73)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Margin Pressure Concerns (4.89%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 48.02x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (12.12x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Negative Free Cash Flow (₹-7.07 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Gujarat Inject Kerala Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Gujarat Inject Kerala Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Gujarat Inject Kerala LtdGujarat Inject ...Selected✓ GUJINJEC • 524238 | 57.4/100 | ₹9.79₹10 | ₹143.41₹143.41 | 48.02Average 48.0 Average | 16.57%Good 16.57% Good | 22.93%Excellent 22.93% Excellent | 0.00Excellent 0.0 Excellent | 79.15%Excellent 79.15% Excellent | 415.26%Excellent 415.26% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1378.90₹1379 | ₹111394.44₹111394.44 | 33.04Average 33.0 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1669.00₹1669 | ₹96034.26₹96034.26 | 26.08Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price111394.44 Cr
Gujarat Inject Kerala Ltd PE Ratio History
Historical price-to-earnings ratio for GUJINJEC — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.07 | ₹25.39 | 362.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Gujarat Inject Kerala Ltd Dividend History
Annual cash dividends paid by GUJINJEC — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹0.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Gujarat Inject Kerala Ltd Quarterly Performance
Latest quarterly metrics for GUJINJEC — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
414.62%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
1600.68%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
415.26%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
79.15%
Compounded annual net profit growth over 5 years
Gujarat Inject Kerala Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GUJINJEC — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Gujarat Inject Kerala Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Gujarat Inject Kerala Ltd (GUJINJEC) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Gujarat Inject Kerala Ltd
About GUJINJEC (Gujarat Inject Kerala Ltd)
Gujarat Inject Kerala Ltd is a dynamic pharmaceutical entity making significant strides in the Indian healthcare landscape. Rooted in a commitment to quality and innovation, the co...mpany diligently sources and distributes a wide array of pharmaceutical products, catering to diverse therapeutic needs. With a strong emphasis on ethical practices and regulatory compliance, GUJINJEC strives to ensure that patients and healthcare professionals have access to reliable and effective medications. Their extensive network and strategic partnerships enable them to efficiently navigate the complexities of the pharmaceutical supply chain, ensuring timely delivery and consistent availability of vital medicines. The company's operations are characterized by a customer-centric approach, focusing on building strong relationships with pharmacies, hospitals, and medical practitioners. GUJINJEC's dedicated team works tirelessly to understand the evolving needs of the market and respond proactively with tailored solutions. This dedication extends beyond mere product distribution; they aim to provide comprehensive support to their partners, fostering a collaborative environment that promotes better patient outcomes. By staying abreast of the latest advancements in pharmaceutical research and technology, GUJINJEC endeavors to contribute to the overall improvement of healthcare standards in India. Operating from its base in Vadodara, India, GUJINJEC leverages its strategic location to efficiently manage its nationwide distribution network. The company maintains a robust infrastructure and adheres to stringent quality control measures throughout its operations. Furthermore, GUJINJEC is committed to sustainable business practices, actively seeking opportunities to minimize its environmental impact and contribute to the well-being of the communities it serves. The company’s unwavering focus on integrity, quality, and customer satisfaction positions it as a trusted and reliable partner in the Indian pharmaceutical industry.
Company Details
Key Leadership
GUJINJEC Share Price: Frequently Asked Questions
What is the current share price of Gujarat Inject Kerala Ltd?
Gujarat Inject Kerala Ltd (GUJINJEC) trades at ₹9.79 on NSE and BSE. Market cap ₹143.41 (Cr). Educational data only.
What is the P/E ratio of Gujarat Inject Kerala Ltd?
Gujarat Inject Kerala Ltd has a P/E of 48.02x vs industry average 34.89x.
What is the Bull Run score for Gujarat Inject Kerala Ltd?
Gujarat Inject Kerala Ltd has a Bull Run score of 57.4/100 based on 25+ financial parameters.
Does Gujarat Inject Kerala Ltd pay dividends?
Gujarat Inject Kerala Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Gujarat Inject Kerala Ltd?
Gujarat Inject Kerala Ltd has ROE of 16.57%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Gujarat Inject Kerala Ltd?
Gujarat Inject Kerala Ltd has debt-to-equity of 0.00.
Is Gujarat Inject Kerala Ltd a good investment?
Bull Run gives Gujarat Inject Kerala Ltd a score of 57.4/100. This is not investment advice — consult a SEBI-registered advisor.